Evidence map›Paper›PMID 35669795›Full record

ArticleJournal of environmental health science & engineering2022

Oxidative degradation of sulfamethoxazole from secondary treated effluent by ferrate(VI): kinetics, by-products, degradation pathway and toxicity assessment.

Behjat Jebalbarezi, Reza Dehghanzadeh, Samira Sheikhi, Najmeh Shahmahdi, Hassan Aslani, Ammar Maryamabadi

Open access · greenAbstract read
In one paragraph

Article in Journal of environmental health science & engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Behjat JebalbareziStudent research committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Reza DehghanzadehStudent research committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Samira SheikhiDepartment of Environmental Health Engineering, Tabriz University of Medical Sciences, Tabriz, Iran.
Najmeh ShahmahdiStudent research committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Hassan AslaniHealth and Environment Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0002-5427-9647
Ammar MaryamabadiR&D Department, Shakheh Zeytoon Lian Co., Bushehr, Iran.
Tabriz University of Medical Sciences · IRBushehr University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulfamethoxazole (SMX) is a typical antibiotic in the world, which is frequently detected in the aquatic environment. The current study was aimed to investigate the SMX degradation in secondary treated wastewater using potassium Ferrate [Fe(VI)]. The effects of various experimental conditions, EDTA and phosphate as chelating agents, and toxicity assessment were also considered. Secondary treated effluent was spiked with predefined SMX concentrations, and after desired reaction time with Fe(VI), residual SMX was measured using HPLC. Results indicated that SMX degradation by Fe(VI) was favored under acidic condition, where 90% of SMX degradation was achieved after 120 min. Fe(VI) and SMX reaction obeyed first-order kinetic; meantime, the SMX degradation rate under pH 3 was 7.6 times higher than pH 7. The presence of phosphate (Na Graphical abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s40201-021-00769-9.

Indexed as

Degradation productsECOSARFe(VI) processSulfamethoxazoleWastewater

Identifiers

PMID35669795
PMCPMC9163226
OpenAlexW4206618927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.